X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with Unichem Lab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs UNICHEM LAB - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH UNICHEM LAB PANACEA BIOTECH/
UNICHEM LAB
 
P/E (TTM) x -19.8 -67.3 - View Chart
P/BV x 2.8 0.8 368.0% View Chart
Dividend Yield % 0.0 2.2 -  

Financials

 PANACEA BIOTECH   UNICHEM LAB
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
UNICHEM LAB
Mar-18
PANACEA BIOTECH/
UNICHEM LAB
5-Yr Chart
Click to enlarge
High Rs149382 38.9%   
Low Rs82234 35.2%   
Sales per share (Unadj.) Rs84.1116.3 72.4%  
Earnings per share (Unadj.) Rs-18.3-18.9 96.8%  
Cash flow per share (Unadj.) Rs-6.7-11.7 57.1%  
Dividends per share (Unadj.) Rs05.00 0.0%  
Dividend yield (eoy) %01.6 0.0%  
Book value per share (Unadj.) Rs83.7381.0 22.0%  
Shares outstanding (eoy) m61.2570.34 87.1%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x1.42.6 51.8%   
Avg P/E ratio x-6.3-16.3 38.8%  
P/CF ratio (eoy) x-17.2-26.2 65.7%  
Price / Book Value ratio x1.40.8 170.7%  
Dividend payout %0-26.4 0.0%   
Avg Mkt Cap Rs m7,07421,668 32.6%   
No. of employees `0002.82.3 120.6%   
Total wages/salary Rs m1,4492,006 72.2%   
Avg. sales/employee Rs Th1,874.13,587.8 52.2%   
Avg. wages/employee Rs Th527.0880.0 59.9%   
Avg. net profit/employee Rs Th-407.7-583.7 69.9%   
INCOME DATA
Net Sales Rs m5,1548,180 63.0%  
Other income Rs m100610 16.4%   
Total revenues Rs m5,2548,790 59.8%   
Gross profit Rs m-766-1,320 58.0%  
Depreciation Rs m711505 140.8%   
Interest Rs m1,50380 1,876.4%   
Profit before tax Rs m-2,881-1,295 222.4%   
Minority Interest Rs m110-   
Prior Period Items Rs m-6-2 259.1%   
Extraordinary Inc (Exp) Rs m1,7710-   
Tax Rs m1733 50.3%   
Profit after tax Rs m-1,121-1,331 84.2%  
Gross profit margin %-14.9-16.1 92.1%  
Effective tax rate %-0.6-2.6 22.6%   
Net profit margin %-21.8-16.3 133.7%  
BALANCE SHEET DATA
Current assets Rs m3,81023,318 16.3%   
Current liabilities Rs m8,3654,635 180.5%   
Net working cap to sales %-88.4228.4 -38.7%  
Current ratio x0.55.0 9.1%  
Inventory Days Days156122 127.9%  
Debtors Days Days67121 55.4%  
Net fixed assets Rs m14,4808,163 177.4%   
Share capital Rs m61141 43.6%   
"Free" reserves Rs m90326,660 3.4%   
Net worth Rs m5,12726,801 19.1%   
Long term debt Rs m5,8323 176,718.2%   
Total assets Rs m19,43331,890 60.9%  
Interest coverage x-0.9-15.2 6.0%   
Debt to equity ratio x1.10 923,737.8%  
Sales to assets ratio x0.30.3 103.4%   
Return on assets %2.0-3.9 -50.1%  
Return on equity %-21.9-5.0 440.4%  
Return on capital %3.6-4.5 -80.1%  
Exports to sales %24.50-   
Imports to sales %10.20-   
Exports (fob) Rs m1,264NA-   
Imports (cif) Rs m525NA-   
Fx inflow Rs m1,5394,356 35.3%   
Fx outflow Rs m9420-   
Net fx Rs m5974,356 13.7%   
CASH FLOW
From Operations Rs m599-1,123 -53.3%  
From Investments Rs m-43816,487 -2.7%  
From Financial Activity Rs m-303-8,811 3.4%  
Net Cashflow Rs m-1416,552 -2.2%  

Share Holding

Indian Promoters % 74.5 50.1 148.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 15.1 4.0%  
FIIs % 1.3 3.0 43.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 31.7 74.4%  
Shareholders   10,259 20,176 50.8%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   CADILA HEALTHCARE  TTK HEALTHCARE  ORCHID PHARMA LTD  DISHMAN PHARMA  J.B.CHEMICALS  

Compare PANACEA BIOTECH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 284 Points Up; FMCG & Metal Stocks Top Gainers(Closing)

Indian share markets settled higher today taking cues from their Asian peers. At the closing bell, BSE Sensex ended up by 284 points.

Related Views on News

UNICHEM LAB Announces Quarterly Results (1QFY19); Net Profit Down 1479.6% (Quarterly Result Update)

Aug 3, 2018 | Updated on Aug 3, 2018

For the quarter ended June 2018, UNICHEM LAB has posted a net profit of Rs 207 m (down 1479.6% YoY). Sales on the other hand came in at Rs 2 bn (down 35.9% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

PANACEA BIOTECH Announces Quarterly Results (4QFY18); Net Profit Down 66.5% (Quarterly Result Update)

Jun 20, 2018 | Updated on Jun 20, 2018

For the quarter ended March 2018, PANACEA BIOTECH has posted a net profit of Rs 86 m (down 66.5% YoY). Sales on the other hand came in at Rs 2 bn (up 0.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Banks are Raising FD Rates and That's Good News(Vivek Kaul's Diary)

Aug 7, 2018

Lending to the retail segment remains strong, whereas lending to the service sector has picked up dramatically.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Aug 17, 2018 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 8-QTR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS